This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. Abbott has agreed to acquire cancer test-maker Exact ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Exact Sciences is adding early cancer detection to its pipeline through its buyout of Thrive Earlier Detection for up to $2.15 billion in cash and stock. The deal comes just three months after Thrive ...

Exact Sciences is an oncology diagnostics company that has a strong position in stool-based DNA testing for colorectal cancer. The cancer diagnostics market is large, and growing, but blood-based ...

Earnings Call Insights: Exact Sciences Corporation (NASDAQ:EXAS) Q4 2024 Kevin Conroy, Chairman and CEO, highlighted Exact Sciences' progress in 2024, including delivering over 4.6 million test ...

Exact Sciences Corporation stock surged after Abbott Laboratories announces a $21bn acquisition at $105 per share, driven by Exact's cancer diagnostics leadership. Exact Sciences boasts strong revenue ...

Shares of diagnostic company Exact Sciences Corporation (NASDAQ:EXAS) fell 5.9% in the morning session after the company reported underwhelming fourth-quarter 2024 results as profit margins worsened ...

Here’s what you should know: 1. Epic will handle multiple components of Exact’s IT system, from “order entry all the way through revenue cycle and customer care,” Exact Sciences CEO Kevin Conroy said ...